How Biotechs Can Win Capital in 2026: Highlights from Evaluate’s Financing Forum
January may be upon us but allow me one chance to look back at one of December’s highlights; Evaluate’s event that took place in London. Evaluate Financing Forum: Biotech Strategies for Accessing Capital saw more than 50 professionals from pharma, biotech and financing come together for a morning of networking and knowledge sharing about biotech […]
Three Things we Learned in our Unlocking Innovation in Pharma Webinar
There is life beyond ADCs and GLP-1s. Given the level of attention these particular areas have received in recent years, it can be hard to remember that – but it was a key message from our recent webinar, “Unlocking Innovation: What pharma deals reveal about tomorrow’s therapies”. Our business development and licensing experts investigated where […]
What Does Dealmaking Tell Us About the Therapies of Tomorrow?
Our upcoming Unlocking Innovation webinar analyzes dealmaking activity to identify mechanisms and technologies that have been trending in recent years, beyond ADCs or GLP-1s. While these two modalities have dominated headlines and investor interest, thanks to their blockbuster potential in oncology and metabolic disease, there’s a broader wave of innovation that could shape the future […]
It’s Time to Act: Why Trump is good for European Biopharma…
Call it a kick up the backside. For decades, Europe has failed to address its biopharma weaknesses – too little lab-to-drug translation, too little scale-up capital, non-existent public markets and penny-pinching drug budgets. Then came President Trump. Love him or hate him, his call-out of the US-EU drug pricing gap, his tariff-talk and his efforts […]
Ready for a Cliffhanger? Register for our Loss of Exclusivity Webinar
For the past few years, our annual World Preview report has included analysis of the potential scale of the 2025-2030 pharma patent cliff. It’s one of the features that garners the most questions from readers, particularly around how a potential loss of $300bn can sit alongside forecast growth of over 7% in the same time […]
How can Pharma Navigate Turbulent Seas? Find out in our World Preview Webinar
The Evaluate World Preview report is a staple of the pharma calendar. The 2025 edition has just been published, marking the 18th year of providing forecast and trend insights to decision makers across the industry. If you’re not familiar with the World Preview, I recommend taking a look. Not only does it provide a wealth […]
Three Things we Learned in our 2025 Preview Webinar
The first Evaluate webinar of the year is in the bag. Based on our 2025 Preview report, this session brought together three of our industry experts to discuss what the year ahead might hold for pharma. They may not have had a crystal ball, but they had plenty of detailed data and insight which is […]
What Will 2025 Hold for Pharma?
Once again, the pharma industry starts a new year with hopes of a recovery. Will 2025 finally see a return of IPOs? Of mega-mergers? Of huge rounds of investment? Perhaps, but more likely this year will simply be a few steps in the right direction. There is still a great deal of uncertainty, particularly around […]
Three Things we Learned in our “Taking the Pharma Industry Pulse” Webinar
One of the great things about working in the pharma industry is the opportunity to listen to very clever people talking about fascinating topics and the latest trends in the market. Events like BIO-Europe are brilliant for this, and there is always plenty to unpack after the panels, keynotes and fireside chats have ended. Our […]
Analogue forecasting: the power of the past to predict the future
Launching a first-in-class drug is high on the wish list of most pharma companies, but achieving that goal is not without its challenges. While patient demand for innovative therapies will always be high, modelling their impact on the treatment landscape is an uncertain business and the stakes are too high to rely on little more […]
